Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden

Currently, cervical cancer prevention is undergoing comprehensive development regarding human papillomavirus (HPV) vaccination and cervical cancer screening. In Sweden and many other countries, high coverage vaccinated cohorts are entering screening within the next few years. This entails demands fo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PloS one Ročník 17; číslo 9; s. e0274825
Hlavní autoři: Kaliff, Malin, Lillsunde Larsson, Gabriella, Helenius, Gisela, Karlsson, Mats G., Bergengren, Lovisa
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Public Library of Science 22.09.2022
Public Library of Science (PLoS)
Témata:
Age
Algorithms
Alphapapillomavirus - genetics
Biobanks
Biology and life sciences
Cancer
Cancer screening
Carcinogens
Cellular biology
Cervical cancer
Cervix
Cytokines
Cytology
Diagnosis
DNA Methylation
Early Detection of Cancer - methods
Female
Genes
Genetic aspects
Genotype
Genotype & phenotype
Genotypes
Genotyping
Human papillomavirus
Humans
Infections
Medical screening
Medicine and Health Sciences
MicroRNAs - genetics
mRNA
Papillomaviridae - genetics
Papillomavirus infections
Papillomavirus Infections - complications
Papillomavirus Vaccines
Research and Analysis Methods
RNA, Messenger
Sweden - epidemiology
Uterine Cervical Neoplasms - diagnosis
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - prevention & control
Vaccines
Vaccines, Combined
Womens health
Sweden
United States > US
ISSN:1932-6203, 1932-6203
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Currently, cervical cancer prevention is undergoing comprehensive development regarding human papillomavirus (HPV) vaccination and cervical cancer screening. In Sweden and many other countries, high coverage vaccinated cohorts are entering screening within the next few years. This entails demands for baseline HPV genotype data across the screening age range for surveillance and a basis for screening program adjustment. In 2016, Örebro County, Sweden, changed to primary HPV screening using HPV mRNA testing followed by cytology triage. An alternative triage method to cytology could allow for a fully molecular screening algorithm and be implemented in a screening program where self-sampling is included. Hypermethylation analysis of the human genes FAM19A4/miR124-2 has been suggested as a promising triage method. HPV mRNA-positive screening samples (n = 529) were included and subjected to genotyping targeting a broad range of both low-risk and high-risk genotypes in addition to hypermethylation analysis of the two human genes FAM19A4/miR124-2. Data were connected to cytological and histological status and age. The most commonly detected genotypes were HPV31, 16, and 52. In addition, HPV18 was one of the most common genotypes in high-grade squamous intraepithelial lesions (HSILs) samples. In relation to available vaccines, 26% of the women with histological HSIL or cancer (≥HSIL) tested positive for only hrHPV included in the quadrivalent vaccine and 77% of the genotypes in the nonavalent vaccine. According to these figures, a relatively large proportion of the HSILs will probably remain, even after age cohorts vaccinated with the quadrivalent vaccine enter the screening program. Hypermethylation positivity was associated with increasing age, but no HPV-related independently predictive factors were found. Accordingly, age needs to be considered in development of future screening algorithms including triage with hypermethylation methodology.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0274825